KPC Pharmaceuticals,Inc.

SHSE:600422 Stock Report

Market Cap: CN¥10.8b

KPC PharmaceuticalsInc Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Wei Yan

Chief executive officer

CN¥2.6m

Total compensation

CEO salary percentagen/a
CEO tenure1.8yrs
CEO ownershipn/a
Management average tenure2.2yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

Solid Earnings May Not Tell The Whole Story For KPC PharmaceuticalsInc (SHSE:600422)

Mar 24
Solid Earnings May Not Tell The Whole Story For KPC PharmaceuticalsInc (SHSE:600422)

Is There An Opportunity With KPC Pharmaceuticals,Inc.'s (SHSE:600422) 35% Undervaluation?

Dec 30
Is There An Opportunity With KPC Pharmaceuticals,Inc.'s (SHSE:600422) 35% Undervaluation?

Does KPC PharmaceuticalsInc (SHSE:600422) Have A Healthy Balance Sheet?

Dec 12
Does KPC PharmaceuticalsInc (SHSE:600422) Have A Healthy Balance Sheet?

Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Nov 18
Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Sep 30
Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Sep 11
These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25
KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

Jun 25
Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04
We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28
KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

CEO

Wei Yan (53 yo)

1.8yrs
Tenure
CN¥2,623,100
Compensation

Mr. Wei Yan is President & Vice Chairman of KPC Pharmaceuticals,Inc since September 28, 2023. Mr. Yan was Vice Chairman of KPC Pharmaceuticals,Inc. from January 19, 2023.

Leadership Team

NamePositionTenureCompensationOwnership
Wei Yan
President & Vice Chairman1.8yrsCN¥2.62mno data
Sun Zhi Qiang
Financial Director2.5yrsCN¥1.62mno data
Zhang Mengxun
Board Secretary & General Counsel5.3yrsCN¥1.44m0.0084%
CN¥ 915.3k
JunFeng Liu
Senior Vice Presidentno dataCN¥2.32m0.020%
CN¥ 2.2m
Li Meng
Executive Vice Presidentno dataCN¥1.89m0.037%
CN¥ 4.0m
Cheng Sun
Vice President1.1yrsno datano data
2.2yrs
Average Tenure
47.5yo
Average Age

Experienced Management: 600422's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wei Yan
President & Vice Chairman2.5yrsCN¥2.62mno data
Ting Guo
Director2.5yrsno datano data
Hui Zhou
Director1.8yrsno datano data
Guihua Wang
Independent Directorless than a yearno datano data
Jin Guo Xin
Independent Director3.6yrsCN¥100.00kno data
Wen Duo Wu
Chairmanless than a yearno datano data
Zheng Liang
Director2.5yrsno datano data
Li Lin Xi
Employee Supervisor6.7yrsno datano data
Zhang Weng Sen
Employee Supervisor6.7yrsno datano data
Hongshen Li
Vice Chairman1.4yrsno datano data
Zhi Yang
Independent Director3.6yrsCN¥100.00kno data
Kang Deng
Supervisor4.3yrsno datano data
2.5yrs
Average Tenure
52yo
Average Age

Experienced Board: 600422's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/16 02:51
End of Day Share Price 2025/07/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

KPC Pharmaceuticals,Inc. is covered by 27 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Pei Hui TangChasing Securities
Pei ChengChina Galaxy Securities Co., Ltd.